eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

vol. 21
Review paper

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

Chrysoula Margioula-Siarkou
1, 2
Stamatios Petousis
1, 2
Alexios Papanikolaou
Giuseppe Gullo
Georgia Margioula-Siarkou
Antonio Simone Laganà
Konstantinos Dinas
Frederic Guyon

Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Gynaecological Oncology Unit, Institut Bergonie, Bordeaux, France
Department of Obstetrics and Gynaecology, Villa Sofia Cervello Hospital, IVF UNIT, University of Palermo, Palermo, Italy
Department of Obstetrics and Gynaecology, “Filippo Del Ponte” Hospital, University of Insubria, Varese, Italy
Menopause Rev 2022; 21(4): 272-275
Online publish date: 2022/12/30
View full text Get citation
PlumX metrics:
Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian cancer introduced the idea of neoadjuvant chemotherapy. The present review aims to summarize current state-of-the-art evidence regarding the efficacy and safety of neoadjuvant chemotherapy as well as novel insights regarding the usage of modern therapeutic regimens in the context of neoadjuvant chemotherapy. The last decade has been characterized by the breakthrough scientific evidence that neoadjuvant chemotherapy followed by interval debulking surgery for advanced-stage ovarian cancer may be comparable to primary debulking surgery. Neoadjuvant chemotherapy followed by interval debulking surgery is an acceptable – if not preferable – therapeutic approach in advanced-staged ovarian cancer patients because it is associated with higher optimal debulking surgery, fewer complications, and non-inferior survival outcomes. The addition of bevacizumab to chemotherapy contributes significantly to survival outcomes without causing side effects that outbalance the benefits. Patients with recurrent high-grade serous ovarian cancer and a germline or breast cancer mutation should be offered maintenance olaparib after a response to platinum-based chemotherapy. Finally, the role of hyperthermic intraperitoneal chemotherapy in the context of neoadjuvant chemotherapy remains unjustified.

neoadjuvant chemotherapy, ovarian cancer, PARP inhibitors, diagnostic laparoscopy, state of the art

Quick links
© 2023 Termedia Sp. z o.o.
Developed by Bentus.